Murray David B, McMillan Ronald, Brower Gregory L, Janicki Joseph S
Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC, USA.
Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H109-16. doi: 10.1152/ajpheart.00968.2008. Epub 2009 May 8.
The objective of this study was to investigate the ability of selective endothelin receptor subtype A (ET(A)) endothelin receptor antagonism (ETA) to prevent the acute myocardial remodeling process secondary to volume overload. Left ventricular tissue from sham-operated (Sham) and untreated (Fist), and TBC-3214 (Fist + ETA, 25 mg.kg(-1).day(-1))-treated fistula animals was analyzed for mast cell density, matrix metalloproteinase (MMP) activity, and extracellular collagen volume fraction (CVF) 1 and 5 days following the initiation of volume overload. Compared with Fist, ETA treatment prevented the increase in left ventricular mast cell density at 1 day and 5 days. Additionally, at 1 day postfistula, a substantial decrease in MMP-2 activity below Sham levels was observed following endothelin receptor antagonism (1.7 +/- 0.7 vs. 0.3 +/- 0.3 vs. 0.9 +/- 0.2 arbitrary activity units, Fist vs. Fist + ETA vs. Sham, P < or = 0.05). This same effect was also seen at 5 days postfistula (1.9 +/- 0.3 vs. 0.5 +/- 0.1 arbitrary activity units, Fist vs. Fist + ETA, P < or = 0.05). The marked decrease in myocardial CVF seen in Fist hearts (0.7 +/- 0.1 vs. 1.6 +/- 0.1% myocardial area, Fist vs. Sham, P < or = 0.05) was prevented by ETA (1.7 +/- 0.1% Fist + ETA, P < 0.05 vs. Fist). This preservation of the collagen matrix was also present on day 5 in the TBC-treated group vs. the Fist group (1.0 +/- 0.1 vs. 1.4 +/- 0.1%, Fist vs. Fist + ETA, P < or = 0.01). Furthermore, an 8-wk preventative treatment with ETA significantly attenuated the increase in left ventricular end systolic and diastolic volumes compared with untreated fistula hearts. In conclusion, the novel findings of this study indicate that the activation of cardiac mast cells and subsequent MMP activation/collagen degradation during the acute stages of volume overload are prevented by blockade of the ET(A) receptor subtype. Furthermore, by preventing these events, ET-1 antagonism was efficacious in attenuating ventricular dilatation and limiting the development of structural and functional deficits.
本研究的目的是探讨选择性内皮素A受体(ET(A))拮抗剂对继发于容量负荷过重的急性心肌重构过程的预防作用。对假手术(Sham)、未治疗(Fist)以及用TBC - 3214(Fist + ETA,25 mg·kg⁻¹·d⁻¹)治疗的瘘管动物的左心室组织,在容量负荷过重开始后的第1天和第5天分析肥大细胞密度、基质金属蛋白酶(MMP)活性以及细胞外胶原容积分数(CVF)。与Fist组相比,ETA治疗可防止第1天和第5天左心室肥大细胞密度的增加。此外,在造瘘后第1天,内皮素受体拮抗后观察到MMP - 2活性大幅下降至低于Sham组水平(1.7±0.7 vs. 0.3±0.3 vs. 0.9±0.2任意活性单位,Fist组 vs. Fist + ETA组 vs. Sham组,P≤0.05)。在造瘘后第5天也观察到同样的效果(1.9±0.3 vs. 0.5±0.1任意活性单位,Fist组 vs. Fist + ETA组,P≤0.05)。Fist组心脏中观察到的心肌CVF显著降低(0.7±0.1 vs. 1.6±0.1%心肌面积,Fist组 vs. Sham组,P≤0.05)被ETA预防(Fist + ETA组为1.7±0.1%,与Fist组相比P < 0.05)。在TBC治疗组与Fist组相比的第5天也存在这种胶原基质的保留(1.0±0.1 vs. 1.4±0.1%,Fist组 vs. Fist + ETA组,P≤0.01)。此外,与未治疗的瘘管心脏相比,ETA进行8周的预防性治疗可显著减轻左心室收缩末期和舒张末期容积的增加。总之,本研究的新发现表明,通过阻断ET(A)受体亚型可预防容量负荷过重急性期心脏肥大细胞的激活以及随后的MMP激活/胶原降解。此外,通过预防这些事件,ET - 1拮抗在减轻心室扩张以及限制结构和功能缺陷的发展方面是有效的。